Phosplatin Therapeutics   Report issue

For profit Phase 2
Founded: New York NY United States (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02266745
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Phosplatin Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (2)

avelumab (bavencio) (1 trial)

pt-112 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2